1168 results about "Therapeutic action" patented technology

A system for treatment of ischemic stroke provides a stroke treatment workflow plan defining series of diagnostic actions and therapeutic actions to be performed at locations within a health care facility identified by beacons detectable by proximity sensors that travel with the patient. A first communications device having wireless communications capabilities receives a signal from a proximity sensor and typically transmits data to a second communications device having a visible timer and configured to receive data from and send data to other wireless communications devices. When the a patient undergoes diagnosis and treatment via the workflow plan, the system tracks the location of the patient within the workflow plan and the time at which the patient is at each location, and records the location of the patient and the time of the location within the workflow plan.

A spine rehabilitation exercise device comprises a soleplate; and an exercise mechanism disposed on the soleplate, wherein the exercise mechanism comprises a sliding mechanism movably disposed on the soleplate; a supporting base movably mounted on top of the sliding mechanism, the supporting base being capable of rocking on top of the sliding mechanism; a pillow mounted on the supporting base; and an elastic assembly disposed between the pillow and the supporting base. The whole device has simple structure, convenient assembly, small and compact volume and good mobility and portability; the device can not only have health care and therapeutic effects on spine, but also be used as a pillow on other occasions, thereby having high practicability and better flexibility in use; moreover, the device is not driven by a power supply, so that it is safer and more reliable to use.

In a subcutaneous implantable cardioverter / defibrillator, cardiac arrhythmias are detected to determine necessary therapeutic action. Cardiac signal information is sensed from far field electrodes implanted in a patient. The sensed cardiac signal information is then amplified and filtered. Parameters such as rate, QRS pulse width, cardiac QRS slew rate, amplitude and stability measures of these parameters from the filtered cardiac signal information are measured, processed and integrated to determine if the cardioverter / defibrillator needs to initiate therapeutic action.

Combination therapies of an opioid receptor agonist and an alpha-2 receptor antagonist in an amount effective to potentiate, but not antagonize, a therapeutic effect of the opioid receptor agonist are provided. Also provided are methods for use of these combination therapies in potentiating the therapeutic effects of opioid receptor agonists, inhibiting development of acute and / or chronic tolerance to opioid receptor agonists and treating conditions treatable by opioid receptor agonist therapy in a subject. In addition, a method for reversing opioid receptor agonist tolerance and / or restoring therapeutic effect of an opioid receptor agonist in a subject via administration of an alpha-2 receptor antagonist in an amount effective to potentiate, but not antagonize, the therapeutic effect of the opioid receptor agonist is provided.

A dual-layer bag catheter is composed of two ball layers and three cavities. Its internal bag layer is used for expanding blood vessel. Its external bag layer made of unique millipore film is used for delivering the therapeutic genes or medicine to the wall of blood vessel or target organ.

The invention discloses a medicinal balloon catheter and a preparation method thereof. The balloon outside surface of the medicinal balloon catheter is grinded and processed through ultraviolet laser to form the concave-convex non-planar structure on the balloon outside surface. The gaps within the non-planar structure form a drug storage layer. The wavelength of the ultraviolet laser is within the range of 10-400nm. The wall thickness of the medicinal balloon catheter is 15-25 microns. The thickness of the non-planar structure is 8-12 microns. Owning to the concave-convex non-planar structure of the balloon outside surface of the medicinal balloon catheter in the invention, the medicinal adsorption storage capacity is fundamentally improved, namely firstly, the amount of the adsorbed medicine is greatly increased, secondly when medicine adsorbed on balloon passes through blood vessels to reach the site of lesion, the medicine adsorbed on the outer wall of the balloon can be maintained as much as possible and cannot be washed off by blood in the blood vessels and cause loss, and can be effectively transferred to the site of lesion by the balloon so as to have effectively therapeutic action. The medicinal balloon catheter of the invention can be used in not only coronary heart disease, but also various diseases caused by other narrow vessels such as lower extremity arterial stenos is or occlusion caused by diabetes.

An antibody against AILIM (alternatively called JTT-1 antigen, JTT-2 antigen, ICOS and 8F4) was found to have a significant therapeutic effect on arthrosis, for example, rheumatoid arthritis and osteoarthritis, graft versus host disease, graft immune rejection, inflammation (hepatitis and inflammatory bowel diseases), diseased condition accompanied by the excessive production of an antibody against a foreign antigen triggered by immunological sensitization by the antigen.

The present invention relates to the use of 3-sbustituted phthalide or analogue for preparing the medicine for treating Alzheimer disease or other neurotic disease. The structural formula is shown in the right formula. Filtering is executed through a high-effective living model which integrates gene technique and biological technique. The research shows that most compounds have a certain function that the defective individual recovers learning capacity, wherein a plurality of specific compounds represent better activity. The learning capacity of deflective individual can be recovered for above 85%. Furthermore a stable treating effect can be shown in a plurality of tests.

Disclosed is a 3-D bioreactor to culture hepatic cells, comprising a culture cavity provided with a cell feeding port and a vent, an inflow cavity with a culture fluid inlet and an outflow cavity with a culture fluid outlet which are arranged next to the culture cavity. A plurality of hollow fibers are arranged inside the culture cavity, each with one end communicated with the inflow cavity and the other end communicated with the outflow cavity, forming a culture fluid flow passage which is communicated with the culture cavity through the tiny holes on the hollow fibers. The invention is characterized in that a 3-d bracket with a plurality of holes is arranged inside the culture cavity. The invention can provide a growth and culture condition that accords better with the physiological environment for the hepatic cells, which is good for culturing dense hepatic cells with high activity so as to ensure the therapeutic effect of a bio-artificial liver with the hepatic cells as the core.

The invention discloses a medicinal composition for treating skin injury and ulcer diseases, and belongs to the field of Chinese medicament. The medicinal composition consists of collagen and Chinesemedicaments for clearing heat and releasing toxin such as coptis root, golden cypress bark, rhubarb, giant knotweed rhizome, honeysuckle flower, forsythia fruit and the like which are prepared into aplurality of dosage forms by matching the prior art. The technology overcomes the defects that the prior common preparations for the trauma department have extremely slow response, longer treatment course, adhesion with the skin, influence on scab cicatrization and the like, has quick and remarkable treatment effect on various skin diabrosis diseases such as mechanical wound, burn / scald, bedsore,chronic leg ulcer, diabetic foot or cancerous ulcer and the like, and can greatly shorten the required time for wound healing and tissue repair.

The invention relates to the technical field of medical instrument cleaning, and discloses a medical instrument cleaning, disinfecting and drying integrated device. The medical instrument cleaning, disinfecting and drying integrated device is characterized in that an electric push rod is arranged on the top of the outer side of a box, a push rod head of the electric push rod extends into the box to be fixedly connected with a cleaning frame, the bottom of the box is provided with an ultrasonic transducer, a first control valve and a second control valve are both solenoid valves, the top of the box is provided with a dryer and an exhaust vent, and the inner side of the top of the box is provided with a plurality of ultraviolet disinfection lamps; and a power module, a controller and a control panel are further included, and the electric push rod, the first control valve, the second control valve, the ultrasonic transducer, the dryer and the multiple ultraviolet disinfection lamps are connected with the controller through the control panel. By means of the medical instrument cleaning, disinfecting and drying integrated device, the workload of cleaning personnel is greatly saved, safety hazards and health hazards are reduced, the cleaning effect is good, and the therapeutic effect of medical instruments is ensured.

The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries.

The invention discloses a compound with thrombolytic activity as well as a preparation method and an application as the thrombolytic agent thereof. The 2-nitrogen or the 3-carboxyl of cyclized dopa is respectively coupled or latticed with H-Ala-Arg-Pro-Ala-Lys-OH, H-Pro-Ala-Lys-OH, H-Arg-Pro-Ala-Lys-OH, H-Gly-Arg-Pro-Ala-Lys-OH or H-Gln-Arg-Pro-Ala-Lys-OH to obtain the compound. The thrombolytic activity of the compound is evaluated by adopting the model of artery-vein bypass cannula thrombus in rats, and the experimental result shows that the compound has the excellent thrombolytic activity and can be clinically used as the thrombolytic agent. The therapeutic action of the compound to the cerebral infarction is further evaluated by adopting the model of cerebral thrombus in rats, and the experimental result shows that the compound has the excellent brain tissue protection action and can be clinically used as the thrombolytic agent.

Desirable fusion proteins can be produced in and purified from the milk of transgenic animals. The peptides are made as fusion proteins with a suitable fusion partner such as human alpha-fetoprotein. The fusion partner protein acts to promote and increase the half-life of the overall molecule as well as having therapeutic effects on its own. The fusion protein is typically produced through the use of transgenic animals and can be purified away from the now the milk or other bodily fluid of such an animal by an affinity purification method. A particular advantage of producing peptides via this route, in addition to the obvious advantages of high yield and biocompatibility, is that specific post-translational modifications, such as carboxy terminal amidation, can be performed in the mammary gland. Biologically active polypeptides comprising a therapeutically active polypeptide fused to human alpha-fetoprotein fragment or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.

The invention discloses a preparation method and application of cycloastragenol. The preparation method of the cycloastragenol comprises the following steps: by using astragaloside or astrasieversianin as a raw material, oxidizing, reducing, hydrolyzing, extracting and purifying to obtain high-purity cycloastragenol. The method is simple to operate, gentle in condition, good in product quality and high in yield. The cycloastragenol can be applied to preparation of anticancer adjuvant therapeutic medicine. An anticancer adjuvane therapeutic medicine prepared by using the cycloastragenol as a pharmaceutical active ingredient has the anticancer adjuvant therapeutic effect of enhancing the anticancer therapeutic effect, reducing the toxicity of the anticancer medicine, preventing and treating the neutropenia caused by the anticancer medicine therapy.

The invention discloses a chimeric antigen receptor containing a CD27 intracellular domain, a lentiviral vector and application thereof. The immune receptor tyrosine activation sequence motif of the chimeric antigen receptor containing CD27 intracellular domain contains CD27molecule intracellular signal domain and T cell costimulatory signal molecules. The CD27molecule intracellular signal domain is connected with costimulatory signals related to T cell activation, so that the in-vitro proliferation and apoptosis effect of T cells can be obviously enhanced, and the ratio of young sample Tscm cells (CD45RA+CD62L+) with in vivo therapeutic action and central memory cells (CD45RO+CD62L+) in CAR-T cells is increased; expression of IL-10 factors capable of restraining immunization is reduced, an obvious effect of improving the CAR-T (T cell chimeric antigen receptor) cellular therapy effect is achieved, and a new idea and a new selection are provided for the field of CAR-T cellular therapy.

The invention discloses a microcapsule floating fluid-bed biological reactor of artificial liver in the medically biological technical domain, which is characterized by the following: displaying hopper shape with small bottom radius and large top radius; setting cell screen 8 at upper neck and cell screen 7 at lower bottom; depositing cell filter 8 at liquid outlet 2; setting buffer cavity 12 between liquid inlet 1 and cell screen 7, and between cell filter 11 and cell screen 8 respectively; containing the microcapsule liver cell 9 between cell screen 8 and cell screen 7; making the liquid inlet connect the membrane oxygenator 14 to connect immune adsorber 15 to adsorb immune macromolecule. The invention makes the moving trail of flow impaction as adjustment parabola to satisfy the character of fluid mechanics, which avoids dead perfusion cavity and ineffective perfusion to develop treating effect of biologically artificial liver obviously.

The invention provides a xylitol-corn silk vinegar beverage and a preparation method thereof, and pertains to the technical field of preparing sugarless functional beverages. The beverage takes a naturally fermented organic acid as an acid ingredient and takes the xylitol as a sweetening agent, and added with corn silk aqueous extract or corn silk aqueous extracted liquid. The xylitol corn silk vinegar beverage has the efficacies of the conventional table vinegar on producing the body fluid and stimulating the appetite, increasing the appetite, reducing blood pressure and the cholesterol in the blood, and preventing arteriosclerosis and certain cancers; and has the functions of the xylitol of providing nutrition and assistant therapeutic action for the diabetic, and preventing and treating dental caries; the corn silk has the efficacies on obviously reducing blood sugar, promoting urination, inhibiting bacterium, reducing blood pressure, enhancing immunity, resisting cancer and the like. The xylitol-corn silk vinegar beverage can be taken as a daily soft drink to replace the alcoholic liquor or conventional drinks, and can be taken as a functional drink for the diabetic or the special groups.

The invention discloses a process for preparing variable zone genes of high affinity tumor necrosis factor (TNF) resistant monoclonal antibody (F6 mAb) comprising, using recombinated human TNF immune BALB / c mouse to prepare a plurality of mouse Anti-TNF monoclonal antibody, screening high affinity F6 mAb using indirect ELISA method. By cloning the monoclonal antibody light chain and heavy chain variable zone genes, the monoclonal antibody light chain and heavy chain variable zone gene sequence and amino acid sequence can be obtained, and the unicity of the gene sequence and protein sequence can be confirmed.

The invention discloses a lanthanide rare earth coordinated cellulose medical material and a preparation method thereof. The medical material is prepared by oxidizing primary hydroxyl of cellulose into carboxyl and then coordinating with lanthanide rare earth metal ions, namely performing sol-gel self-assembling reaction to rare earth metal hydrate and cellulose the primary hydroxyl of which is selectively oxidized into carboxyl. The preparation method is simple in preparation technology and good in controllability. The material not only has excellent moisture absorption and preservation properties and breathability, and better biocompatibility and excellent degradability of cellulose materials, but also has antibacterial property of the rare earth complex, can be used for antibacterial and bacteriostasis wound dressing due to broad-spectrum antibacterial property, and can also be used for detection tracing, special marking and optical display of biomolecules; the lanthanide rare earth coordinated cellulose medical material can be prepared into powder, gel, thin films, sponge or other porous materials, thus expanding the clinical application range; and the lanthanide rare earth coordinated cellulose medical material can be doped or grafted with macromolecular compounds so as to enhance the antibacterial and bacteriostasis properties and promote therapeutic effect on wound recovery.

IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

The invention relates to a point eye mask and a preparation and application thereof, the point eye mask comprises a back lining layer, a drug storage layer and a protective layer, wherein, the drug storage layer is formed by coating the drug emulsion containing PSA (pressure sensitive adhesive), skin transdermal enhancer and other drugs onto the back lining layer, wherein, the drug emulsion is formed by blending nano-powder of Chinese herbal extract for szechwan lovage rhizome, radix salviae miltiorrhizae, angelica sinensis, chrysanthemum, plantago asiatica, semen celosiae, cuscuta chinensis lam, equisetum hiemale linne, fructus ligustri lucidi, radix glycyrrhiza, and cassia seed and the like; a polyester film protective layer is covered onto the back lining layer, and the eye mask is formed through cutting. The point eye mask adopts principles of traditional Chinese acupuncture and release and control technology of modern transdermal, can constantly release active ingredients in points for a long period of time, can well adjust and improve muscles, nerves, and blood vessels at and around the eyes, can play a certain role in delaying for development of myopia of young people, and play a role in treatment for fatigue blurred vision, high intraocular pressure, presbyopia, and dry eye syndrome. Meanwhile, the invention has advantages of convenient using, persistent efficacy.

An agent for preventing or treating portal hypertension comprising a compound represented by the general formula (I): wherein R<1 >represents a group capable of forming an anion, etc.; X represents a bond or a spacer; n is an integer of 1 or 2; ring A is benzene ring which may be further substituted; R<2 >represents a group capable of forming an anion, etc.; and R<3 >represents a hydrocarbon group which may bonded via a hetero atom, and may be substituted, a salt thereof or a prodrug thereof, is provided. This agent has sufficiently excellent properties as medicine, since it has excellent prophylactic and therapeutic effects on portal hypertension without any side effect, etc.

The present invention is directed to a novel use of pyridone derivatives such as pirfenidone for the prevention and treatment of damages to tissues or organs induced by various cytotoxic agents, such as chemotherapeutic agents, biologics, immunosuppressants and radiation. Such prophylactic and / or therapeutic effects of the pyridone derivatives make it possible to increase therapeutic dosages of the cytotoxic agent, thereby enhancing the therapeutic efficacy of the cytotoxic agent and radiation therapy.